復星醫藥(02196.HK)子公司與復地產發擬共同設立蘇州星晨 以於蘇州市設立並運營營利性三級兒童醫療機構
格隆匯10月11日丨復星醫藥(02196.HK)公佈,2021年10月11日,公司控股子公司復星健康與關聯方復地產發籤訂《合資協議書》,擬共同投資設立蘇州星晨。新公司的註冊資本為人民幣7,000萬元,其中:復星健康擬現金出資人民幣3,570萬元認繳新公司註冊資本的51%、復地產發擬現金出資人民幣3,430萬元認繳新公司註冊資本的49%。新公司擬藉助雙方股東各自資源和產業優勢,於江蘇省蘇州市設立並運營營利性三級兒童醫療機構。
據悉,復地產發成立於2018年8月,註冊地為中國上海,法定代表人為王基平。復地產發的經營範圍包括企業管理諮詢,市場營銷策劃,展覽展示服務,會務服務,廣吿設計、製作、代理、發佈,房地產開發經營,物業管理,房地產租賃經營,計算機軟硬件的安裝、維護,貨物或技術的進出口(國家禁止或涉及行政審批的貨物和技術除外),建築裝飾裝修建設工程設計與施工,建築材料、金屬材料的銷售[依法須經批准的項目,經相關部門批准後方可開展經營活動]。截至本公吿日,豫園股份(公司控股股東復星高科技直接及間接合計持有其68.59%的股權)持有復地產發100%的股權。
公司表示,本次投資旨在利用雙方各自資源和產業優勢,通過設立合資公司,在蘇州定位兒童醫療高端市場,運營營利性三級兒童醫療機構,以進一步強化本集團在長三角區域的醫療服務業務佈局。本次投資完成後,集團將持有新公司51%的股權,新公司將納入集團合併報表範圍。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
![](/hk/assets/image/code.84ab0b.png)
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.